Will StudyFetch actually help me do better on my exams?

Yes. StudyFetch builds a personalized study plan from your materials, breaking them into an ordered sequence of topics so you learn things the right way. Instead of guessing what to review, you get flashcards, quizzes, practice tests, and more built from exactly what you need to know.

How does StudyFetch know what I need to study?

StudyFetch reads your materials and identifies the key topics, then organizes them into a study plan that tells you what to learn, in what order, and tracks what you've already covered. You always know exactly where you are and what to focus on next.

How do I know if I'm actually learning?

StudyFetch shows you which topics you've already covered and uses your study plan to surface what you still need to know. It organizes your materials into the most effective learning order, so you always know where you stand and what to focus on next.

What if my exam is tomorrow?

Your study plan has a cram mode that picks out the most important things you need to know for your exam. Even if you're starting the night before, you get the key concepts front and center so you can make the most of the time you have.

Top students are already using StudyFetch to prepare for the MCAT, NCLEX, LSAT, GMAT, board exams, AP exams, and everything in between. Whatever you're studying for, StudyFetch helps you study smarter and show up ready.

How is StudyFetch different from ChatGPT or NotebookLM?

ChatGPT and NotebookLM are general-purpose tools. StudyFetch is built entirely for studying. Your materials stay organized in one place, so you never have to re-upload or start from scratch. StudyFetch turns your content into flashcards, quizzes, practice tests, audio recaps, explainer videos, and study games, and it learns with you over time to help you study more effectively.

How much does StudyFetch cost?

Getting started with StudyFetch is free. Upload your materials, try the study tools, and see what clicks. Students who go premium make StudyFetch their full study system.

Does this work with my class?

Upload your own PDFs, slides, documents, lecture recordings, images of notes, or YouTube video links. StudyFetch builds everything from your specific materials, not generic content. If you can read it or listen to it, StudyFetch can learn from it.

Can StudyFetch help me study anything?

Yes. You don't even need to upload materials. Just type in a topic you want to learn about and StudyFetch will find information and build study tools around it. Whether it's for a class or just something you're curious about, StudyFetch can help you learn it.

Can I use StudyFetch during my lectures?

Yes. Record your class lectures directly in StudyFetch, and it turns them into study materials for you. No more scrambling to take notes or worrying about missing something important. Just hit record, focus on the lecture, and let StudyFetch handle the rest.

What if I don't learn well from just reading notes?

StudyFetch gives you multiple ways to study the same material. Listen to audio recaps on the go, watch explainer videos, play study games for active recall, or take practice tests to simulate the real thing. You pick what works for your learning style.

What if I'm stuck on something and don't understand it?

Ask Sparky. Your learning companion can explain any concept from your materials in a way that makes sense to you. Ask follow-up questions, request a different explanation, or have Sparky walk you through it step by step until it clicks.

Can I trust the AI-generated study tools?

Every flashcard, quiz question, and study tool StudyFetch creates comes with citations back to your original materials. You can see exactly where each piece of information came from, so you always know it's grounded in what your professor actually gave you.

Does StudyFetch work on my phone?

Yes. Web, iOS, and Android. Your study materials sync across all your devices so you can study anywhere.

Is my uploaded content private?

Yes. Your uploaded materials are private by default. You control who can see them.

Malignant Germ Cell Tumors of the Ovary: Diagnosis and Treatment Study Guide

This guide provides an overview of cytoreductive surgery for recurrent ovarian cancer. It covers the goals of surgery, the importance of patient selection using tools like the AGO Score and iMODEL, and the analysis of key clinical trials (DESKTOP III, SOC-1, GOG-213). Learn about the factors influencing clinical decision-making, such as platinum sensitivity and performance status, and how surgery is integrated with chemotherapy for optimal patient outcomes.

Save this study guide to your study set

Your learning path

NCCN Guidelines for Ovarian Cancer

Clinical practice guidelines for the diagnosis, staging, and treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.

Fallopian tube cancer
Primary peritoneal cancer
Pathologic staging
Germline and somatic biomarker testing
BRCA1/2 status
Homologous recombination deficiency (HRD)
PARP inhibitor (PARPi) maintenance therapy
Neoadjuvant therapy
Response interval debulking surgery (IDS)
Optimal cytoreduction
Hyperthermic intraperitoneal chemotherapy (HIPEC)
Systemic therapy regimens
Low-grade serous carcinoma
Clear cell carcinoma
Mucinous neoplasms
Malignant germ cell tumors

Ovarian Tube Cancer Management

NCCN Guidelines for the diagnosis, primary treatment, maintenance therapy, and monitoring of ovarian, fallopian tube, and primary peritoneal cancer.

Surgical staging
Tumor cytoreductive surgery
Neoadjuvant therapy
Adjuvant therapy
Platinum-based therapy
Maintenance therapy
PARPi therapy
BRCA1/2 germline and somatic status
HRD status
Tumor markers
Platinum-sensitive disease
Platinum-resistant disease
Less common ovarian cancers (LCOC)
Carcinosarcoma
Clear cell carcinoma
Mucinous neoplasms
Small cell carcinoma of the ovary (hypercalcemic type)

Ovarian Carcinoma Systemic Therapy and Management

NCCN Guidelines for systemic therapy regimens, recurrence therapy, and monitoring for small cell carcinoma of the ovary (hypercalcemic type), grade 1 endometrioid carcinoma, and low-grade serous carcinoma.

Small cell carcinoma of the ovary (hypercalcemic type)
Endometrioid carcinoma
Low-grade serous carcinoma
Systemic therapy regimens
Primary therapy
Recurrence therapy
Hormonal therapy
Aromatase inhibitors
Chemotherapy
Biomarker testing
MSI/MMR testing
Tumor biomarker testing
Monitoring and follow-up
Surgical staging
Platinum-sensitive disease
Platinum-resistant disease

Ovarian Serous Borderline Epithelial Tumors

Guidelines regarding pathology (low malignant potential).

Ovarian serous borderline epithelial tumors
Low malignant potential
Low-grade serous carcinoma
Adjuvant treatment
Surgical resection
Completion surgery
Fertility-sparing surgery
Pathologic diagnosis
Lymph node evaluation
Chemotherapy

Ovarian Serous Borderline and Sex Cord-Stromal Tumors

NCCN Guidelines for the monitoring, diagnosis, and treatment of ovarian serous borderline epithelial tumors and malignant sex cord-stromal tumors.

Ovarian serous borderline epithelial tumors
Malignant sex cord-stromal tumors
Fertility-sparing surgery
Platinum-based chemotherapy
Surgical debulking
Inhibin levels
Recurrence therapy

Malignant Germ Cell Tumors Treatment Guidelines

NCCN Guidelines for the management of malignant germ cell tumors including surgical principles, chemotherapy, and monitoring/follow-up.

Malignant germ cell tumors
Fertility-sparing surgery
Complete staging surgery
Dysgerminoma
Immature teratoma
Embryonal carcinoma
Endodermal sinus tumor (yolk sac tumor)
Nongestational choriocarcinoma
Adjuvant treatment
High-dose chemotherapy
Hematopoietic cell transplant (HCT)
Tumor markers
Surveillance
Second-line chemotherapy

Malignant Germ Cell and Sex Cord-Stromal Tumors

NCCN Guidelines for systemic therapy regimens, recurrence therapy, and surveillance for malignant germ cell and sex cord-stromal tumors.

Systemic therapy regimens
Malignant germ cell tumors
Malignant sex cord-stromal tumors
Primary therapy
Recurrence therapy
High-dose chemotherapy
Post-treatment surveillance
Tumor markers
Imaging
Carboplatin/Paclitaxel
Etoposide/Cisplatin
Granulosa cell tumors

Imaging and Surgery for Ovarian Cancer

NCCN Guidelines for imaging workup, treatment response assessment, monitoring, and surveillance of ovarian, fallopian tube, and primary peritoneal cancer.

Principles of imaging workup
Treatment response assessment
Monitoring and follow-up of LCOCs
Surveillance of malignant germ cell tumors
Surveillance of sex cord-stromal tumors
Principles of surgery
Surgical staging and debulking procedures
Operative report requirements

Surgical Management and Staging in Ovarian Cancer

Primary Debulking and Extended Surgery in Ovarian Cancer

Comparison of primary cytoreduction and extended surgery outcomes including survival impact of diaphragmatic surgery, splenectomy, and porta hepatis surgery.

Primary cytoreduction
Extended surgery
Optimal cytoreduction
Diaphragmatic surgery
Liver surgery
Splenectomy
Pancreatectomy
Progression-free survival
Overall survival

Predicting Optimal Debulking in Ovarian Cancer

This content discusses the categorization of Stage III and IV ovarian cancer and the use of imaging modalities and laparoscopy to predict optimal debulking surgery.

Stage III ovarian cancer categorization
Stage IV ovarian cancer management
Primary debulking surgery (PDS)
Neoadjuvant chemotherapy (NACT)
Interval debulking surgery (IDS)
Residual disease
Computed tomography (CT) prediction models
Magnetic resonance imaging (MRI) prediction models
Positron emission tomography (PET/CT) prediction models
Diagnostic laparoscopy
Suboptimal cytoreduction

Ovarian Cancer Staging and Survival

Ovarian cancer staging involves classification of tumor extension, histological subtypes, and survival rates based on treatment outcomes.

Stage I ovarian cancer
Stage II ovarian cancer
Stage III cancer
Stage IV ovarian cancer
Peritoneal metastasis
Malignant cells in ascites
Histological subtypes
Serous ovarian carcinoma
Endometrioid ovarian carcinoma
Mucinous ovarian carcinoma
Clear-cell ovarian carcinoma
Overall survival
Residual disease
Debulking surgery
Sugarbaker Index

Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer

Secondary cytoreductive surgery
Recurrent ovarian cancer
AGO Score
Progression-free interval (PFI)
Complete resection
Residual disease (RD)
FIGO stage
ECOG performance status
Ovarian adenocarcinoma types
High-grade serous adenocarcinoma
Low-grade serous adenocarcinoma
Mucinous adenocarcinoma
Endometrioid adenocarcinoma
Clear cell adenocarcinoma
Progression-free survival (PFS)
Time to third line (TFST)
Overall survival (OS)
AGO DESKTOP III trial design
cytoreductive surgery
platinum-based chemotherapy

Primary and Interval Debulking in Advanced Ovarian Cancer

Comparison of primary debulking surgery and neoadjuvant chemotherapy followed by interval debulking surgery, including FIGO staging, diagnostic laparoscopy, and survival outcomes related to residual disease.

Primary debulking surgery (PDS)
Neoadjuvant chemotherapy (NACT)
Interval debulking surgery (IDS)
Progression-free survival (PFS)
Overall survival (OS)
Residual disease levels
Pathologic complete response (pCR)
Chemotherapy pathologic scores
High-grade serous ovarian cancer (HGSOC)
Complete gross resection (CGR)
Tumor biology and chemosensitivity
Type 1 and Type 2 ovarian cancer
FIGO staging system for ovarian cancer (EOC)
Diagnostic laparoscopy
Suboptimal cytoreduction
Peritoneal carcinomatosis
Oophorectomy
Hysterectomy
Preoperative assessment
Cytoreductive surgery

Immune Response and Management of Gynecological Cancers

Immune Response and Heterogeneity in Gynecological Cancers

This presentation examines the immune response and heterogeneity in gynecological cancers, focusing on ovarian cancer, endometrial cancer, and biomarkers of response to check-point inhibitors.

Ovarian cancer heterogeneity
High-grade serous ovarian cancer (HGSOC)
BRCA and HRD
Tumor infiltrating lymphocytes (TILs)
Neoantigen load
Clear cell ovarian carcinoma immune microenvironment
MSI-H (hyper-mutated)
POLE (ultra-mutated)
Check-point inhibitors

Biomarkers for Checkpoint Blockade Immunotherapy

Biomarkers for checkpoint blockade immunotherapy response include tumor neoantigen burden, microsatellite instability, high tumor mutational burden, and PD-L1 protein expression.

checkpoint blockade immunotherapy
tumor neoantigen burden
microsatellite instability (MSI)
high tumor mutational burden (TMB)
PD-L1 protein expression
T cell–inflamed tumor microenvironment (TME)
gene signatures of activated T cells
tumor-infiltrating lymphocytes (TILs)
POLE mutation
MSH6 hyper-mutated phenotype
combination therapy with antiangiogenic and PARPi

ESGO-ESMO Consensus on Advanced Ovarian Cancer

Consensus recommendations for the management of advanced stage ovarian cancer including primary debulking surgery, neoadjuvant chemotherapy, and bevacizumab use.

primary debulking surgery
neoadjuvant chemotherapy
bevacizumab
carboplatin and paclitaxel
weekly chemotherapy regimens
intraperitoneal chemotherapy
hyperthermic intraperitoneal chemotherapy
low grade serous ovarian carcinoma
mucinous ovarian carcinoma
clear cell ovarian carcinoma
progression-free survival
overall survival

Management of Non High Grade Serous Ovarian Carcinoma

Summary of recommendations and clinical data regarding management of non high grade serous epithelial ovarian carcinoma including surgery, chemotherapy, and anti oestrogen therapy.

Secondary debulking surgery
Low grade serous ovarian carcinoma
Low grade endometrioid ovarian carcinoma
Mucinous ovarian carcinoma
Clear cell ovarian carcinoma
Anti oestrogen therapy
Chemotherapy efficacy
Complete cytoreduction
Progression free survival
Overall survival
BRAF inhibitors
MEK1/2 inhibitors

Management of Recurrent Ovarian Cancer

Summary of recommendations regarding monitoring, surgery, molecularly targeted therapy, platinum resistance, and maintenance therapy for recurrent ovarian cancer.

monitoring and follow-up strategy
cytoreductive surgery
molecularly targeted therapy
bevacizumab
PARP inhibitors
platinum resistance
platinum sensitivity
platinum-rechallenge
maintenance therapy
quality of life

Surgical Principles and Pathological Assessment

Surgical Management of Invasive Epithelial Ovarian Cancer

Guidelines for primary cytoreduction, interval debulking surgery, and surgical procedures for invasive epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Primary cytoreduction
Interval debulking surgery
Neoadjuvant chemotherapy
Omentectomy
Para-aortic lymph node dissection
Pelvic lymph node dissection
Peritoneal cytologic examinations
HIPEC with cisplatin
Optimal cytoreduction
Bilateral salpingo-oophorectomy (BSO)
Hysterectomy
Unilateral salpingo-oophorectomy (USO)

Systemic Therapy for Ovarian and Fallopian Tube Cancer

Principles of systemic therapy including PARP inhibitor maintenance and primary chemotherapy regimens for various stages of ovarian, fallopian tube, and primary peritoneal cancer.

PARP inhibitor maintenance therapy
Post-primary treatment maintenance
Post-recurrence treatment maintenance
Niraparib monotherapy
Olaparib monotherapy
Rucaparib monotherapy
Olaparib and Bevacizumab combination
Niraparib and Bevacizumab combination
Platinum-based therapy
BRCA1/2-mutated disease
High-grade serous carcinoma
Endometrioid carcinoma
Clear cell carcinoma
Carcinosarcoma
Mucinous carcinoma
Low-grade serous carcinoma
Chemotherapy toxicity monitoring
Hypersensitivity reaction management
Myelosuppression

Systemic Therapy for Ovarian Cancer Recurrence

Systemic therapy for recurrent ovarian, fallopian tube, and primary peritoneal cancer include platinum-sensitive and platinum-resistant disease regimens.

Platinum-sensitive disease therapy
Platinum-resistant disease therapy
Cytotoxic therapy
Targeted therapy
Hormone therapy
Immunotherapy
Tumor biomarker testing
BRAF V600E-positive tumors
NTRK1/2/3 gene fusion-positive tumors
HER2-positive tumors
FRα-expressing tumors
RET gene fusion-positive tumors
Low-grade serous carcinoma
Mucinous carcinoma
dMMR/MSI-H recurrent or advanced tumors

Management of Chemotherapy Drug Reactions

Guidelines for managing infusion and allergic reactions associated with platinum agents, taxanes, liposomal doxorubicin, and biotherapeutic agents in gynecologic oncology.

infusion reactions
hypersensitivity reactions
anaphylaxis
platinum agents
taxane drugs
biotherapeutic agents
carboplatin
cisplatin
oxaliplatin
paclitaxel
docetaxel
liposomal doxorubicin
H1 blocker antihistamine
H2 blockers
corticosteroids
epinephrine
desensitization

Topic 30

Pathology, Biology, and Classification of Ovarian Carcinoma

Pathology and Biology of Ovarian Carcinoma

Discussion of epithelial ovarian carcinoma pathogenesis, molecular events, histotypes, and grading according to WHO 2014.

low grade serous
high grade serous
mucinous
endometrioid
clear cell
seromucinous
undifferentiated
pathogenesis
molecular events
carcinoma grading
WT1
BRCA
p53 testing

Ovarian Pathology and Quantum Mechanics Overview

This collection of documents discusses ovarian pathology, including seromucinous carcinoma and serous carcinoma, alongside fundamental principles of quantum mechanics.

Ovarian carcinoma
seromucinous tumour
low grade serous carcinoma
high grade serous carcinoma
borderline tumours
intraepithelial carcinoma
quantum mechanics
wave-particle duality
superposition
Schrödinger equation
Dirac notation
quantum computing
quantum cryptography

Molecular Biology of High Grade Serous Ovarian Carcinoma

This document discusses Tp53 mutations, BRCA1/2 abnormalities, and the clinical behaviour of high grade serous and low grade serous ovarian carcinomas.

Tp53 mutations
High grade serous carcinoma
Low grade serous carcinoma
Wild-type immunoreactivity
Mixed ovarian carcinomas
Clinical behaviour and prognosis

Pathology and Molecular Biology of Ovarian Neoplasms

This document discusses the pathology, molecular events, and genetic mutations associated with various ovarian epithelial and sex cord-stromal tumours.

Endometrioid adenocarcinoma
Clear cell carcinoma
Ovarian mucinous tumours
Adult granulosa cell tumour
Small cell carcinoma of the ovary, hypercalcemic type
PTEN mutations
K-RAS mutations
ARID1A mutations
FOXL2 mutation
DICER1 mutations
SMARCA4/BRG1 mutations
SMARCB1/INI1 mutations
Endometriosis-associated ovarian neoplasms

Classifications and Subtypes of Ovarian Cancer

Ovarian cancer subtypes are classified by origin, histology, genomics, and clinical characteristics including stage and response to platinum.

High-grade serous carcinoma (HGSC)
Endometrioid carcinoma
Mucinous carcinoma
Clear cell carcinoma
Germ cell tumors
Sex-cord stromal tumors
Type I and Type II ovarian cancer
Peritoneal dissemination
Fallopian tube role in tumorigenesis
Immunophenotype
FIGO staging
Meso-molecular subtype

Ovarian Cancer Classifications and Molecular Targets

This topic covers histological subtypes of ovarian cancer, molecular characteristics of epithelial ovarian cancer, and molecular targets in ovarian cancer treatment.

High-grade serous carcinoma
Low-grade serous carcinoma
Endometrioid carcinoma
Mucinous carcinoma
Clear cell carcinoma
BRCA1/2 protein DNA double strand break repair
PARP proteins DNA damage repair
Synthetic lethal interactions
Homologous recombination deficiency (HRD)
PI3K/AKT/mTOR pathway
MAPK/ERK pathway
17β-estradiol formation in cancer cells
Type I and Type II ovarian cancer classification

Diagnosis, Staging, and Surgical Management

Ovarian, Fallopian Tube, and Peritoneal Cancer Management

This document provides clinical guidelines for the diagnosis and treatment of various ovarian cancer histotypes, including low-grade serous carcinoma, borderline epithelial tumors, malignant germ cell tumors, and malignant sex cord-stromal tumors.

Low-grade serous carcinoma
High-grade serous carcinoma
MAPK pathway mutations
TP53 mutations
Maintenance hormone therapy
MEK inhibitors
Fertility-sparing surgery
Malignant germ cell tumors
Dysgerminomas
Immature teratomas
Endodermal sinus tumors
Malignant sex cord-stromal tumors
Granulosa cell tumors
Adjuvant chemotherapy
Systemic therapy sequencing
Tumor marker monitoring
Management of drug toxicities

Recurrent Ovarian Cancer Treatment Options

Recommendations for PARP inhibitors, targeted agents, and immunotherapy in patients with recurrent ovarian, fallopian tube, and primary peritoneal cancer.

PARP inhibitors
platinum-resistant disease
platinum-sensitive disease
BRCA1/2 P/S mutations
FRα expression
HER2-positive tumors
dabrafenib and trametinib
BRAF V600E mutation
NTRK inhibitors
RET gene fusion
pembrolizumab
mismatch repair deficient disease
dostarlimab-gxly
less common ovarian cancers

Ovarian Cancer Management and Histologic Types

Clinical recommendations for surgical staging, fertility-sparing surgery, and adjuvant therapy across various ovarian cancer histologies including clear cell carcinoma, mucinous carcinoma, and carcinosarcomas.

Fertility-sparing surgery
Comprehensive surgical staging
Clear cell carcinoma
Platinum-based regimens
Immunotherapy (ipilimumab/nivolumab)
Bevacizumab
Mucinous carcinoma
Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT)
SMARCA4 gene mutations

Ovarian Cancer Treatment and Management References

This document provides a comprehensive list of clinical references regarding ovarian, fallopian tube, and primary peritoneal cancer treatments.

adjuvant chemotherapy
neoadjuvant chemotherapy
debulking surgery
interval debulking surgery
platinum-based chemotherapy
carboplatin
paclitaxel
cisplatin
bevacizumab
maintenance olaparib
rucaparib
intraperitoneal chemotherapy
hormone replacement therapy
geriatric assessment

Phase III Surgical Trials for Recurrent Ovarian Cancer

Cytoreductive Surgery in Recurrent Ovarian Cancer

Analysis of clinical trials including DESKTOP III, SOC-1, and GOG-213 regarding the impact of cytoreductive surgery on progression-free survival and overall survival in recurrent ovarian cancer.

Cytoreductive surgery
Recurrent ovarian cancer
Progression-free survival (PFS)
Overall survival (OS)
DESKTOP III trial
SOC-1 trial
AGO score
iMODEL selection criteria
Platinum-based chemotherapy
Complete resection rate
Bevacizumab

Management of Oncology Drug Reactions

Laboratory Studies and Biomarkers in Ovarian Cancer

Appropriate laboratory studies and tumor markers including CA-125, AFP, and CEA are used for preoperative workup, treatment planning, and monitoring response to therapy in patients with ovarian cancer.

Complete blood count (CBC)
Chemistry profile
Liver function test
Cancer antigen 125 (CA-125)
Lactate dehydrogenase (LDH)
Carcinoembryonic antigen (CEA)
Performance status
Nutritional status evaluation
Mucinous tumors
Stromal or germ cell tumors

Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Guidelines

Ovarian Cancer Surgical and Systemic Management

Clinical guidelines for debulking surgery, neoadjuvant chemotherapy, adjuvant systemic therapy, maintenance PARP inhibitors, and monitoring for recurrent disease in ovarian, fallopian tube, and primary peritoneal cancer.

Optimal cytoreduction
Debulking surgery
Neoadjuvant chemotherapy (NACT)
Interval debulking surgery (IDS)
Hyperthermic intraperitoneal chemotherapy (HIPEC)
Systematic lymphadenectomy
Adjuvant systemic chemotherapy
Platinum-based regimens
Bevacizumab
Maintenance therapy
PARP inhibitors
BRCA1/2 mutations
Homologous recombination repair (HR) status
Circulating tumor DNA (ctDNA) assays
Platinum-sensitive disease
Platinum-resistant disease

Laboratory Studies and Biomarker Tests

Therapy for Recurrent Platinum-Sensitive Ovarian Cancer

Patients with recurrent platinum-sensitive high-grade ovarian cancer may be treated with multiple platinum-based combination regimens including bevacizumab.

platinum-sensitive high-grade disease
platinum-based combination chemotherapy
carboplatin/paclitaxel
carboplatin/liposomal doxorubicin
platinum/gemcitabine regimens
bevacizumab
taxane hypersensitivity
progression-free survival
overall survival
adverse events

Management of Specific Ovarian Cancer Histologies

Ovarian Cancer Histological Types and Research

This document provides a bibliography of clinical studies and consensus reviews regarding various ovarian, fallopian tube, and primary peritoneal cancers.

ovarian carcinosarcoma
clear cell ovarian cancer
mucinous adenocarcinoma of the ovary
small cell carcinoma of the ovary-hypercalcemic type
low-grade serous carcinoma
serous tumors of low malignant potential
borderline ovarian neoplasms
platinum-based chemotherapy
immune checkpoint blockade
hormonal maintenance therapy

Ovarian and Germ Cell Tumor Management

This document provides a bibliography of clinical studies regarding the management, surgical staging, and chemotherapy of ovarian germ cell tumors, stromal cell tumors, and granulosa cell tumors.

surgical staging
conservative management
platinum-based chemotherapy
immature teratoma
growing teratoma syndrome
ovarian stromal cell tumors
granulosa cell tumors
adjuvant chemotherapy
salvage therapy

Make it your own.

Keep these readings and topics in a new study set, or add them to one you already use.

Get started free Log in